alectinib + capmatinib

Alectinib + capmatinib is an investigational combination therapy consisting of two oral small molecule tyrosine kinase inhibitors, each targeting distinct oncogenic drivers in non-small cell lung cancer (NSCLC). Alectinib is a highly selective inhibitor of anaplastic lymphoma kinase (ALK), approved for the treatment of ALK-positive NSCLC. Capmatinib is a selective MET inhibitor, approved for NSCLC with MET exon 14 skipping mutations or MET amplification. The rationale for combining these agents arises from the observation that acquired resistance to ALK inhibitors in ALK-rearranged NSCLC can occur via secondary activation or amplification of the MET pathway. Dual inhibition with alectinib and capmatinib aims to overcome this resistance mechanism by simultaneously blocking both ALK and MET signaling pathways. Early clinical reports suggest moderate antitumor activity and manageable safety profiles in patients with concurrent ALK rearrangement and acquired MET amplification[1][2]. This regimen remains investigational, primarily used off-label or within clinical studies.

Other names

alectinib + capmatinib combination therapy